ID: ALA5194991

Max Phase: Preclinical

Molecular Formula: C22H18N4O4

Molecular Weight: 402.41

Representations

Canonical SMILES:  N#Cc1ccc(Oc2ccc3nc(OCC(=O)N4CCNC(=O)C4)ccc3c2)cc1

Standard InChI:  InChI=1S/C22H18N4O4/c23-12-15-1-4-17(5-2-15)30-18-6-7-19-16(11-18)3-8-21(25-19)29-14-22(28)26-10-9-24-20(27)13-26/h1-8,11H,9-10,13-14H2,(H,24,27)

Standard InChI Key:  WMRIIVBFHZNKQZ-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 402.41

Molecular Weight (Monoisotopic): 402.1328

AlogP: 2.24

#Rotatable Bonds: 5

Polar Surface Area: 104.55

Molecular Species: NEUTRAL

HBA: 6

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 8

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 13.69

CX Basic pKa: 2.29

CX LogP: 1.77

CX LogD: 1.77

Aromatic Rings: 3

Heavy Atoms: 30

QED Weighted: 0.70

Np Likeness Score: -1.55

References

1. Patel MV, Peltier HM, Matulenko MA, Koenig JR, C Scanio MJ, Gum RJ, El-Kouhen OF, Fricano MM, Lundgaard GL, Neelands T, Zhang XF, Zhan C, Pai M, Ghoreishi-Haack N, Hudzik T, Gintant G, Martin R, McGaraughty S, Xu J, Bow D, Kalvass JC, Kym PR, DeGoey DA, Kort ME..  (2022)  Discovery of (R)-(3-fluoropyrrolidin-1-yl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)quinolin-2-yl)methanone (ABBV-318) and analogs as small molecule Na_v1.7/ Nav1.8 blockers for the treatment of pain.,  63  [PMID:35436748] [10.1016/j.bmc.2022.116743]

Source

Source(1):

• Scientific Literature